Renal Pelvis and Ureter Urothelial Carcinoma

Renal Pelvis and Ureter Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

52 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 30
Recruiting: 16
Ph III recruiting: 4
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 51–52 of 52 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03935347	Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy	withdrawn	Phase 2	0	Roswell Park Cancer InstituteOTHER	1	Jan 2, 2020	clinicaltrials
NCT02178241	Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery	completed	Phase 2	26	National Cancer Institute (NCI)NIH	2	Dec 16, 2019